Login / Signup

Preparation of a Zirconium-89 Labeled Clickable DOTA Complex and Its Antibody Conjugate.

Falguni BasuliOlga VasalatiyJianfeng ShiKelly C LaneFreddy E EscorciaRolf E Swenson
Published in: Pharmaceuticals (Basel, Switzerland) (2024)
Desferrioxamine B (DFO) is the clinical standard chelator for preparing zirconium-89 labeled antibodies. In the current study, the stabilities of a zirconium-89 labeled panitumumab (PAN; Vectibix ® ) with three different chelators (DFO, DFO*, and DOTA) were compared. PAN is an anti-HER1/EGFR monoclonal antibody approved by the FDA for the treatment of HER1-expressing colorectal cancers and was used as the model antibody for this study. DFO/DFO* conjugates of PAN were directly radiolabeled with zirconium-89 at room temperature to produce [ 89 Zr]Zr-DFO/DFO*-PAN conjugates following a well-established procedure. A zirconium-89 labeled DOTA-PAN conjugate was prepared by an indirect radiolabeling method. A cyclooctyne-linked DOTA chelator (BCN-DOTA-GA) was first radiolabeled with zirconium-89 at 90 °C under a two-step basic pH adjustment method followed by conjugation with PAN-tetrazene at 37 °C to produce a labeled conjugate, BCN-[ 89 Zr]Zr-DOTA-GA-PAN. High reproducibility of the radiolabeling was observed via this two-step basic pH adjustment. The overall radiochemical yield was 40-50% (n = 12, decay uncorrected) with a radiochemical purity of >95% in 2 h synthesis time. All three conjugates were stable in whole human serum for up to 7 days at 37 °C. The kinetic inertness of the conjugates was assessed against the EDTA challenge. BCN-[ 89 Zr]Zr-DOTA-GA-PAN exhibited excellent inertness followed by [ 89 Zr]Zr-DFO*-PAN. [ 89 Zr]Zr-DFO-PAN displayed the lowest level of inertness.
Keyphrases
  • pet imaging
  • pet ct
  • positron emission tomography
  • cancer therapy
  • room temperature
  • computed tomography
  • monoclonal antibody
  • small cell lung cancer
  • mass spectrometry
  • young adults
  • ionic liquid
  • replacement therapy